PMC full text:
Published online 2020 Oct 21. doi: 10.1016/j.bbrc.2020.10.042
Table 3
Summary of Current Clinical Trials using Ivermectin for SARS-CoV-2.
| Title, URL | Statusa | Nb | Interventionsc | Start | Locations | |
|---|---|---|---|---|---|---|
| 1 | Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19; https://ClinicalTrials.gov/show/NCT04381884 | R | 45 | Ivermectin 0.6 mg/kg QD plus SC vs. SC | 18.5.20 | CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina |
| 2 | Ivermectin and Nitazoxanide Combination Therapy for COVID-19; https://ClinicalTrials.gov/show/NCT04360356 | NY | 100 | Ivermectin 0.2 mg/kg once plus NZX 500 mg BID for 6 days vs. SC | 20.5.20 | Tanta University, Egypt |
| 3 | Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19; https://ClinicalTrials.gov/show/NCT04429711 | R | 100 | Ivermectin 12–15 mg/day for 3 days vs. Placebo | 12.5.20 | Sheba Medical Center, Ramat-Gan, Israel |
| 4 | Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection; https://ClinicalTrials.gov/show/NCT04391127 | A | 200 | Ivermectin 12 mg (<80 kg) or 18 mg (>80 kg) once vs. HCQ 400 mg BID for 1 day then 200 mg BID for 4 days vs. Placebo | 4.5.20 | Jose Manuel Arreola Guerra, Aguascalientes, Mexico |
| 5 | Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19; https://ClinicalTrials.gov/show/NCT04405843 | R | 400 | Ivermectin 0.3 mg/kg daily for 5 days vs. Placebo | 20.6.20 | Colombia |
| 6 | Ivermectin In Treatment of COVID 19 Patients; https://ClinicalTrials.gov/show/NCT04425707 | R | 100 | Ivermectin (dose unlisted) vs. SC vs. Ivermectin (dose unlisted) plus SC | 9.6.20 | Isolation and referral hospitals for COVID 19 patients, Cairo, Egypt |
| 7 | Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection; https://ClinicalTrials.gov/show/NCT04407130 | E | 72 | Ivermectin 0.2 mg/kg once plus 200 mg DOC day 1 followed by 100 mg DOC BID for 4 days vs. Ivermectin 0.2 mg/kg QD for 5 days vs. Placebo | 16.6.20 | ICDDR, Dhaka, Bangladesh |
| 8 | Efficacy of Ivermectin as Add on Therapy in COVID19 Patients; https://ClinicalTrials.gov/show/NCT04343092 | C | 100 | Ivermectin 0.2 mg/kg once weekly plus HCQ 400 mg QD plus ATM 500 mg QD vs. HCQ 400 mg QD plus ATM 500 mg QD | 18.4.20 | General Directorate of Medical City, Bagdad, Baghdad, Iraq |
| 9 | COVidIVERmectin: Ivermectin for Treatment of Covid-19 (COVER); https://ClinicalTrials.gov/show/NCT04438850 | R | 102 | Ivermectin 0.6 mg/kg QD for 5 days vs. Ivermectin 1.2 mg/kg QD for 5 days vs. Placebo | 20.6.20 | Negrar, Verona, Italy; Bologna, Italy; Milan, Italy; Rovereto, Italy; Turin, Italy; Barcelona, Spain; Madrid, Spain |
| 10 | Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms (SILVERBULLET); https://ClinicalTrials.gov/show/NCT04407507 | NY | 66 | Ivermectin 12 mg/day for 3 days plus paracetamol 500 mg QID for 14 days vs. Placebo plus paracetamol 500 mg QID for 14 days | 20.6.20 | Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V., Mexico |
| 11 | Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial (SAINT); https://ClinicalTrials.gov/show/NCT04390022 | A | 24 | Ivermectin 0.4 mg/kg once vs. Placebo | 14.5.20 | Clinica Universidad de Navarra, Pamplona, Navarra, Spain |
| 12 | A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh; https://ClinicalTrials.gov/show/NCT04434144 | C | 116 | Ivermectin 0.2 mg/kg once plus DOC 100 mg BID for 10 days vs. HCQ 400 mg day 1 then 200 mg BID for 9 days plus ATM 500 mg/day for 5 days | 2.5.20 | Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh |
| 13 | Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection (IDRA-COVID19); https://ClinicalTrials.gov/show/NCT04435587 | NY | 80 | Ivermectin 0,6 mg/kg daily for 3 days vs. HCQ 400 mg BID Day 1 then 200 mg BID for 4 days plus Darunavir/ritonavir (400 mg/100 mg) BID for 5 days | 20.7.20 | Siriraj Hospital, Bangkok Noi, Bangkok, Thailand |
| 14 | IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19; https://ClinicalTrials.gov/show/NCT04425863 | A | 100 | Ivermectin 5 mg/ml oral to be repeated 1 week later (dose unlisted) | 1.5.20 | Hospital Eurnekian, Buenos Aires, Argentina |
| 15 | A Preventive Treatment for Migrant Workers at High-risk of Covid-19; https://ClinicalTrials.gov/show/NCT04446104 | C | 5000 | Ivermectin 12 mg once vs. HCQ 400 mg day 1 then 200 mg/day for 42 days vs. Zinc 80 mg/day plus vitamin C 500 mg/day for 42 days vs. Povidone-iodine throat spray TID for 42 days vs. Vitamin C 500 mg/day for 42 days | 13.5.20 | Tuas South Dormitory, Singapore, Singapore |
| 16 | New Antiviral Drugs for Treatment of COVID-19; https://ClinicalTrials.gov/show/NCT04392427 | NY | 100 | Ivermectin (dose unlisted) plus NZX (dose unlisted) plus ribavirin 200 mg or 400 mg vs. Control (untreated) | 20.5.20 | Mansoura University, Mansoura, Select A State Or Province, Egypt |
| 17 | Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN); https://ClinicalTrials.gov/show/NCT04447235 | R | 176 | Ivermectin 12 mg once plus losartan 50 mg/day for 15 days vs. Placebo | 20.7.20 | Instituto do Cancer do Estado de São Paulo, Brazil |
| 18 | Ivermectin in Treatment of COVID-19; https://ClinicalTrials.gov/show/NCT04445311 | R | 100 | Ivermectin daily (dose unlisted) for 3 days plus SC vs. SC | 31.5.20 | Waheed Shouman, Zagazig, Sharkia, Egypt |
| 19 | Efficacy of Ivermectin in COVID-19; https://ClinicalTrials.gov/show/NCT04392713 | R | 100 | Ivermectin 12 mg once plus SC vs. SC | 15.4.20 | Combined Military Hospital Lahore, Lahore, Punjab, Pakistan |
| 20 | Ivermectin and Doxycycine in COVID-19 Treatment; https://ClinicalTrials.gov/show/NCT04403555 | R | 40 | Ivermectin (dose unlisted) plus DOC (dose unlisted) vs. CQ (dose unlisted) | 1.6.20 | Sherief Abd-Elsalam, Tanta, Egypt |
| 21 | The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment; https://ClinicalTrials.gov/show/NCT04351347 | R | 300 | Ivermectin (dose unlisted) vs. Ivermectin (dose unlisted) plus NZX (dose unlisted) vs. Ivermectin (dose unlisted) plus CQ (dose unlisted) | 16.6.20 | Tanta University, Tanta, Egypt |
| 22 | Prophylactic Ivermectin in COVID-19 Contacts; https://ClinicalTrials.gov/show/NCT04422561 | Cd | 304 | Ivermectin (dose unlisted) 2 doses 72 h apart vs. Control (untreated) | 31.5.20 | Zagazig University, Zagazig, Sharkia, Egypt |
| 23 | Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study; https://ClinicalTrials.gov/show/NCT04373824 | R | 50 | Ivermectin 0.2–0.4 mg/kg daily for 2 days plus SC vs. SC | 25.4.20 | Max Super Speciality Hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India |
| 24 | A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19 (IFORS); https://ClinicalTrials.gov/show/NCT04431466 | R | 64 | Ivermectin 0.1 mg/kg once vs. Ivermectin 0.1 mg/kg day 1 and repeated after 72 h vs. Ivermectin 0.2 m/kg once vs. Ivermectin 0.2 mg/kg day 1 and repeated after 72 h vs. SC | 1.7.20 | Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil |
| 25 | Novel Agents for Treatment of High-risk COVID-19 Positive Patients; https://ClinicalTrials.gov/show/NCT04374019 | R | 240 | Ivermectin 12 mg (<75 kg) or 15 mg (>75 kg) daily for 2 days vs. HCQ 600 mg/day for 14 days plus ATM 500 mg day 1 then 250 mg/day for 4 days vs. Camostat Mesilate 200 mg TID for 14 days vs. Artemesia annua 50 mg TID for 14 days | 1.5.20 | University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States |
| 26 | Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19; https://ClinicalTrials.gov/show/NCT04399746 | Ce | 30 | Ivermectin 6 mg/day on days 0, 1, 7 and 8 plus ATM 500 mg/day 4 days plus Cholecalciferol 400 IU BID for 30 days vs. Control (untreated) | 15.3.20 | Outpatient treatment, Mexico City, Mexico |
| 27 | USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR); https://ClinicalTrials.gov/show/NCT04425850 | Af | 1195 | Ivermectin (topical for oral mucosae) plus iota carrageenan (topical for oral mucosae) 5 times per day plus PPE vs. PPE only | 1.6.20 | Hospital Eurnekian, Buenos Aires, Argentina |
| 28 | Novel Regimens in COVID-19 Treatment; https://ClinicalTrials.gov/show/NCT04382846 | NY | 80 | Ivermectin plus CQ (dose unlisted) vs. Ivermectin plus NZX (dose unlisted) vs. Ivermectin plus NZX plus ATM (dose unlisted) vs. NZX and ATM (dose unlisted) | 8.5.20 | Tanta University, Egypt |
| 29 | Anti-Androgen Treatment for COVID-19; https://ClinicalTrials.gov/show/NCT04446429 | R | 254 | Ivermectin 0.2 mg/kg QD plus ATM 500 mg QD vs. Ivermectin 0.2 mg/kg QD plus ATM 500 mg QD plus Dutasteride 0.5 mg QD | 26.6.20 | Corpometria Institute, Brasilia, Brazil |
| 30 | A Real-life Experience on Treatment of Patients With COVID 19; https://ClinicalTrials.gov/show/NCT04345419 | R | 120 | Ivermectin (dose unlisted) vs. CQ (dose unlisted) vs. Favipiravir (dose unlisted) vs. NZX (dose unlisted) vs. Niclosamide (dose unlisted) vs. other drugs (oseltamivir or combination of above, dose unlisted) | 16.6.20 | Tanta University Hospital, Tanta, Egypt |
| 31 | Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic (observational); https://ClinicalTrials.gov/show/NCT04460547 | NY | 200 | Completed interventional vs. completed observational studies on Ivermectin, Convalescent Plasma, HCQ, DAS181, or Interferon β1A | 25.7.20 | Qassim University, Saudi Arabia |
| 32 | Trial of Combination Therapy to Treat COVID-19 Infection; https://ClinicalTrials.gov/show/NCT04482686 | NY | 300 | Ivermectin (dose unlisted) day 1 and 4 plus DOC (dose unlisted) for 10 days plus Zinc for 10 days plus Vitamin D3 for 10 days plus Vitamin C for 10 days vs. Placebo | 22.7.20 | ProgenaBiome, California, USA |
| 33 | Randomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19; https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001994-66/ES | O | 266 | Ivermectin (dose unlisted) vs. Placebo | 8.5.20 | Fundació Assistencial Mútua Terrassa, Spain |
| 34 | Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and manifested clinical symptoms; https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002091-12/BG | O | 120 | Ivermectin 0.4 mg/kg plus SC vs. Placebo plus SC | 5.5.20 | Bulgaria (9 sites) |
| 35 | Efficacy of hydroxychloroquine, ciclesonide and ivermectin in treatment of moderate covid-19 illness: an open-label randomised controlled study (EHYCIVER-COVID); http://ctri.nic.in/Clinicaltrials CTRI/2020/04/024948 | NY | 120 | Ivermectin 12 mg/day for 7 days vs. Ciclesonide 0.2 mg/kg BID for 7 days vs. HCQ 400 mg BID Day 1 then 200 mg BID for 6 days vs. SC | 15.5.20 | New Delhi, India |
| 36 | A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection; http://ctri.nic.in/Clinicaltrials CTRI/2020/04/025068 | NY | 50 | Ivermectin 3 mg (15-24 kg) or 6 mg (25-35 kg) or 9 mg (36-50 kg) or 12 mg (51-65 kg) or 15 mg (66-79 kg) or 0.2 mg/kg (80 kg) once vs. SC | 27.5.20 | Christian Medical College Vellore, Tamil Nadu, India |
| 37 | Interventional study to assess the efficacy of Ivermectin with standard of care treatment versus standard of care in patients of COVID-19 at R D Gardi Medical College, Ujjain, India; http://ctri.nic.in/Clinicaltrials CTRI/2020/04/025224 | NY | 50 | Ivermectin 12 mg/day for 2 days plus SC vs. SC | 24.5.20 | R D Gardi Medical College, Ujjain, Madhya Pradesh, India |
| 38 | Study to assess the efficacy of Ivermectin as prophylaxis of COVID 19 among health care workers and COVID 19 contacts in Ujjain, India; http://ctri.nic.in/Clinicaltrials CTRI/2020/04/025333 | NY | 2000 | Ivermectin 12 mg/day (adult) or 6 mg/day (children) for 2 days vs. Control | 27.5.20 | R D Gardi Medical College, Ujjain, Madhya Pradesh, India |
| 39 | Randomised Controlled Trial of Ivermectin in hospitalised patients with COVID19 (RIVET-COV); http://ctri.nic.in/Clinicaltrials CTRI/2020/04/026001 | NY | 60 | Ivermectin single dosing of 0.2 mg/kg vs. Ivermectin 0.4 mg/kg vs. Ivermectin 0.8 mg/kg vs. Ivermectin 1.6 mg/kg vs. Ivermectin 2 mg/kg vs. SC | 25.6.20 | New Delhi, India |
| 40 | A Prospective, randomized, single centred, open labelled, two arm, placebo-controlled trial to evaluate efficacy and safety of Ivermectin drug in patients infected with SARS-CoV-2 virus; http://ctri.nic.in/Clinicaltrials CTRI/2020/04/025960 | NY | 100 | Ivermectin 12 mg/day for 3 days vs. SC | 18.6.20 | Symbiosis University Hospital and Research Centre, Maharashtra, India |
| 41 | A Clinical Trial to Study the Efficacy of “Ivermectin” in the prevention of Covid-19. A Single Arm Study; http://ctri.nic.in/Clinicaltrials CTRI/2020/04/026232 | NY | 50 | Ivermectin 0.2 mg/kg once | 10.7.20 | DVFM, Andhra Pradesh, India |
| 42 | Ivermectin Nasal Spray for COVID19 Patients; https://ClinicalTrials.gov/show/NCT04510233 | NY | 60 | Ivermectin nasal spray (1 ml) in each nostril BID vs. Ivermectin oral (6 mg) TID vs. SC | 10.8.20 | Tanta University, Tanta, Egypt |
| 43 | Outpatient use of ivermectin in COVID-19; https://ClinicalTrials.gov/show/NCT04530474 | NY | 200 | Ivermectin 0.15–0.2 mg/kg (max 12 mg) once vs. Placebo | 26.8.20 | Temple University Hospital, Philadelphia, USA |
| 44 | Ivermectin to prevent hospitilizations in COVID-19; https://ClinicalTrials.gov/show/NCT04529525 | R | 500 | Ivermectin 12 mg (48-80 kg) or 18 mg (80-110 kg) or 24 mg (>100 kg) at inclusion and again at 24h vs. Placebo | 21.8.20 | Ministry of Public Health, Province of Corrientes, Argentina |
| 45 | Clinical trial of ivermectin plus doxycycline for the treatment of confirmed Covid-19 infection; https://ClinicalTrials.gov/show/NCT04523831 | Cg | 400 | Ivermectin 6 mg and DOC 100 mg BID for 5 days vs. Placebo | 19.8.20 | Dhaka Medical College, Dhaka Bangladesh |
| 46 | Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission; https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001474-29/ES | O | 24 | Ivermectin (dose unlisted) vs. Placebo | 8.5.20 | Clinica Universidad de Navarra, Pamplona, Spain |
| 47 | Dose-Finding study of Ivermectin treatment on patients infected with Covid-19:A clinical trial; https://en.irct.ir/trial/47012 | A | 125 | Ivermectin 0.2 mg/kg single dose plus SC vs. Ivermectin 0.2 mg/kg day 1, 2, 5 plus SC vs Placebo plus SC vs. Ivermectin 0.4 mg/kg day 1 and 0.2 mg/kg day 2, 5 vs. SC | 4.5.20 | Qazvin University of Medical Sciences, Qazvin, Iran |
| 48 | In vivo use of ivermectin (IVR) for treatment for corona virus infected patients: a randomized controlled trial; http://www.chictr.org.cn/showprojen.aspx?proj=54707 | NY | 60 | Ivermectin single dose 0.2 mg/kg vs. Placebo | 10.6.20 | Rayak Hospital, Riyaq, Lebanon |
| 49 | A randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19); http://en.irct.ir/trial/48444 | A | 60 | Ivermectin 0.15–0.2 mg/kg single dose day 1 plus HCQ 200 mg day 1 plus Lopinavir/Ritonavir 400/100 mg days 2–6 vs. HCQ 200 mg day 1 plus Lopinavir/Ritonavir 400/100 mg days 2–6 | 30.5.20 | Ahvaz Razi Hospital, Ahvaz, Iran |
| 50 | A double-blind clinical trial to repurpose and assess the efficacy and safety of ivermectin in COVID-19; http://isrctn.com/ISRCTN40302986 | R | 45 | Ivermectin 6 mg every 3.5 days for 2 weeks vs. Ivermectin 12 mg every 3.5 days for 2 weeks vs. Placebo | 23.4.20 | Lagos University Teaching Hospital, Lagos, Nigeria |
| 51 | Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020; https://en.irct.ir/trial/49174 | R | 60 | Ivermectin 0.2 mg/kg single dose plus SC vs. SC | 21.5.20 | Bouali Hospital, Sari, Iran |
| 52 | Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients; https://clinicaltrials.gov/ct2/show/study/NCT04472585 | R | 40 | Ivermectin 0.2 mg/kg subcutaneous injection every 2 days plus SC vs. Ivermectin 0.2 mg/kg subcutaneous injection every 2 days plus 80 mg/kg Nigella Sativa oral QD plus SC vs. Ivermectin 0.2 mg/kg subcutaneous injection every 2 days plus 20 mg Zinc Sulfate oral TID plus SC vs. Placebo plus SC | 14.7.20 | Shaikh Zayed Hospital, Lahore, Pakistan |
| 53 | Pragmatic study "CORIVER": Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19); https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001971-33/ES | O | 45 | Ivermectin 0.2–0.4 mg/kg (regime unlisted) vs. HCQ 400 mg vs ATM 500 mg vs. Placebo | 22.7.20 | Hospital Universitario Virgen de las Nieves, Granada, Spain |
| 54 | Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel at All Levels of Care, During the 2020 Pandemic: A Randomized Clinical Controlled Trial; https://clinicaltrials.gov/ct2/show/record/NCT04527211 | NY | 550 | Ivermectin 0.2 mg/kg weekly for 7 weeks vs. Placebo | 7.9.20 | Pontificia Universidad Javeriana, Valle Del Cauca, Colombia |
| 55 | Ivermectin Inhalation Forms in the Management of COVID-19 Egyptian Patients; https://clinicaltrials.gov/ct2/show/NCT04510233 | NY | 60 | Ivernectin nasal spray BID (dose unlisted) vs. Ivermectin oral 6 mg TID vs. SC | 10.8.20 | Tanta University, Tanta, Egypt |
| 56 | Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19. https://clinicaltrials.gov/ct2/show/NCT04551755 | NY | 188 | Ivermectin 12 mg first dose then 12 mg after 12 h plus DOC 100 mg BID for 10 days vs. Placebo | 16.9.20 | Bangladesh Medical College Hospital, Dhaka, Bangladesh |
| 57 | Comparative Study of Hydroxychloroquine and Ivermectin in Covid-19 Prophylaxis; https://clinicaltrials.gov/ct2/show/NCT04384458 | R | 400 | Ivermectin (dose based on weight, unlisted) QD for 2 days repeated every 14 days for 45 days plus 20 mg BID active Zinc versus HCQ 400 mg BID on day 1, and QD on days 2–5 followed by QD every 5 days for 50 days plus 20 mg BID active Zinc | 12.5.20 | Drug Research and Development Centre, Federal University of Ceará, Ceará, Brazil |
| 58 | Assessment of response of ivermectin on virological clearance in COVID 19 patients; http://ctri.nic.in/Clinicaltrials CTRI/2020/08/027394 | NY | 56 | Ivermectin 0.2 mg/kg single dose vs. SC | 26.08.20 | Maulana Azad Medical College, New Delhi, India |
| 59 | Evaluation of the effect of ivermectin on patients with COVID-19; http://en.irct.ir/trial/50305 | C | 130 | Ivermectin 0.2 mg on day 1 followed by 3 mg BID days 2–4 plus HCQ sulfate and ATM (both according to protocol of Ministry of Health) vs. HCQ sulfate and ATM alone | 23.08.20 | Tehran University of Medical Sciences, Tehran, Iran |
| 60 | Prophylactic Ivermectin in COVID 19 Contacts http://ctri.nic.in/Clinicaltrials; CTRI/2020/08/027282 | NY | 180 | Ivermectin 12 mg once vs. Ivermectin 36 mg once vs. Placebo | 20.08.20 | Government Institute of Medical Sciences Greater Noida, Uttar Pradesh, India |
| 61 | Ivermectin as a possible treatment for COVID-19; http://ctri.nic.in/Clinicaltrials CTRI/2020/08/027225 | NY | 90 | Ivermectin 12 mg QD on days 1–2 vs. Placebo | 18.08.20 | AAIMS, Patna, India |
| 62 | Evaluating the effect of Ivermectin on covid 19 patients; http://en.irct.ir/trial/49935 | R | 60 | Ivermectin 14 mg every 12 h for 36 h then again on day 7 vs. Placebo | 06.08.20 | Ahvaz University of Medical Sciences, Ahvaz, Iran |
| 63 | Evaluate the Efficacy of Siddha Treatment in Patients with Novel Coronavirus Infectious Disease; http://ctri.nic.in/Clinicaltrials CTRI/2020/08/026999 | R | 100 | Ivermectin 12 mg once plus DOC 100 mg BID for 5 days plus Vitamin C 500 mg QD plus Zinc QD plus SC vs. Siddha traditional medicine protocol for 7 days | 05.08.20 | Indian Medicine and Homeopathy Department, Tamil Nadu, India |
| 64 | Ivermectin effect in the treatment of patients with covid-19; http://en.irct.ir/trial/49180 | R | 40 | Ivermectin 0.2 mg/kg QD for 2 days vs. antiviral drugs (eg. HCQ) as per SC | 20.07.20 | Mashhad University of Medical Sciences, Mashhad, Iran |
| 65 | Randomized phase IIA clinical trial to compare the efficacy of ivermectin versus placebo to obtain negative PCR results in patients with early phase Covid-19; PER-034-20 | R | 68 | Ivermectin 0.3 mg/kg QD for 3 days vs. Placebo | 17.07.20 | Universidad Peruana Cayetano Heredia, Lima, Peru |
| 66 | Evaluation of ivermectin effects on Covid-19; http://en.irct.ir/trial/49280 | R | 50 | Ivermectin 0.15 mg/kg/day plus SC vs. SC | 22.08.20 | Kermanshah University of Medial Sciences, Kermanshah, Iran |
| 67 | A placebo-controlled, randomized, double-blind study in COvid-19 patients with iveRmectin; An inVEstigator iniTiaTEd trial (CORVETTE-01); jRCT2031200120 | R | 240 | Ivermectin 0.2 mg/kg once vs. Placebo | 16.09.20 | Kitasato University Hospital, Kanagawa, Japan |
| 68 | A single-centre, open-label, randomized controlled study of ivermectin treated mild to moderate COVID-19 cases; Debidwar Upazila Health Complex | Ch | 62 | Ivermectin 0.2 mg/kg once plus SC vs. SC | 01.05.20 | Debidwar Upazila Health Complex, Comilla, Bangladesh |
aR, Recruiting, NY, Not yet recruiting, A, Active not recruiting, C, Completed, E, Enrolling by invitation, O, ongoing.
bNumber of patients.
cSC, standard care, QD, once per day, BID, twice daily, QID, 4 times daily, TID, 3 times daily, PPE, personal protective equipment, vs. versus, HCQ, hydroxychloroquine; DOC, doxycycline; CQ, chloroquine, ATM, Azithromycin, NZX, Nanozoxide
dRaw data for asymptomatic family close contacts of confirmed COVID patients show that 2 doses of ivermectin 72 h apart resulted in only 7.4% of 203 subjects reporting symptoms of SARS-CoV-2 infection, in contrast to 101 control untreated subjects, of whom 58.4% reported symptoms; evidence of prophylaxis by ivermectin.
eRecovery rate of the 28 patients that received ivermectin/AZM/cholecalciferol was 100%, with mean symptomatic recovery 3.6 days (negative PCR confirmed day 10). Imaging on day 10 showed improvement in all patients with pneumonia. Authors conclude the combination therapy might mitigate disease progression without significant adverse effects but further studies required (preferably controlled) [46].
fPreliminary results for 1195 subjects consistent with prophylaxis effected by ivermectin/carrageenan topical combination [47].
gRaw data shows a significant reduction in the number of 183 patients with late clinical recovery (requiring >12 days to show clinical improvement) in the ivermectin/DOC group compared to placebo (23 versus 37.2%), as well as a significant reduction (8.7 versus 17.8%) in patients showing clinical deterioration (from mild/moderate to moderate or severe), and a significant reduction (7.7 versus 20%) in persistent Covid-19 positive patients at 14 days compared to 180 control patients; evidence of efficacy for ivermectin/DOC.
hNo statistically significant clinical benefit in 32 treated subjects compared to 30 subjects given placebo, but authors concluded study requires confirmation with larger numbers of subjects [48].
